Longevity has plenty of opinions.
Medicine needs frameworks.

Exceptional aging is no longer theoretical — superaging research shows a measurable pattern (metabolic, cognitive, hormonal, inflammatory, social), actionable earlier than medicine has traditionally engaged. Dr. Shepherd maps what the evidence reveals about exceptional healthspan, where it diverges from the standard of care, and what a patient-centered longevity ecosystem looks like in practice.

Longevity care has gotten good at measurement; the harder question is what to do with it. Dr. Lin offers a framework for turning labs, wearables, imaging, hormones, and AI outputs into care plans patients can follow — separating what's ready for practice now from what's still premature, against real constraints like time, workflow, and economics.

Physician leaders across longevity, precision medicine, and women's health have the conversation most conferences are too polished to have: what's clinically ready today, what's promising but premature, and what's noise dressed up in the language of science. Distinct lenses, a willingness to disagree publicly, and audience questions driving the second half.

GLP-1 receptor agonists are the most consequential development in metabolic medicine in a generation — and the most overhyped. Dr. Barzilai brings the missing rigor: cardiovascular outcomes, neurological signals, lean-mass implications, and the patient profiles where these agents belong in a longevity protocol versus where they don't.

AI is being positioned as the solution to every problem in medicine; this panel maps where that framing breaks down. Drawing on AI development in regulated healthcare, the clinical precision-medicine lens, and the health-system view, it examines where AI genuinely augments judgment, where it's sold faster than it can be validated, and the part of the physician's role it can't replace.

Epigenetic clocks, multi-system biomarkers, and organ-specific aging scores have outpaced the framework for interpreting them. Dr. Sehgal — who developed SYMPHONYAge, measuring biological aging across eleven organ systems from a single blood draw — gives physicians a working decision framework: which tests are validated, what they predict, and when more data creates more confusion than clarity.

The therapies clinicians are asked about — peptides, IV nutrients, regenerative biologics, compounded GLP-1s — are evolving faster than the frameworks built to manage them. This session establishes the landscape before implementing new protocols: how the FDA, DEA, state boards, and compounding rules interact, where the greatest exposure lies, and what separates a defensible practice from an enforcement action.

Standard cardiovascular risk tools were built on male physiology — and for women, particularly in peri- and postmenopause, they miss. Dr. Steinbaum lays out a framework for female cardiovascular biology: which biomarkers matter, where AI-enhanced imaging changes risk stratification, and what a clinician seeing women in midlife can do differently today.

The microbiome shapes cardiovascular, metabolic, immune, and cognitive aging — but the clinical signal has been buried under consumer-grade testing that generates anxiety without action. This session covers what the science supports: how to interpret AI-driven metagenomic microbiome analysis in a longevity context, and how to build interventions that move the needle.

Skin is the only organ you can see without a scan — and most clinicians underuse it as a diagnostic tool. This panel reframes skin aging as a mitochondrial, hormonal, metabolic, and inflammatory conversation: the same processes driving cardiovascular disease, cognitive decline, and metabolic dysfunction are written on the skin years before they show up elsewhere.

Declining estrogen and progesterone alter gut motility, visceral sensitivity, and the gut-brain axis — producing a picture in perimenopausal women that's often indistinguishable from IBS, frequently comorbid, and almost never evaluated hormonally. This session names the diagnostic problem: telling primary IBS from perimenopause-induced symptoms from true overlap, and where sequential single-specialty care breaks down.

The longevity market is already being built — by investors, entrepreneurs, and consumer brands moving faster than any clinical guideline. This moderated conversation examines the forces reshaping patient expectations and the investment signals driving the next decade of health infrastructure, and what the clinical community must do to lead the shift rather than follow it.

For women, people of color, and anyone outside the original study cohort, medicine's slow-by-design caution has too often meant wrong — PCOS took 17+ years to reach consensus; the BMI scale, derived from 1800s European men, is still used across every demographic. This panel examines what happens when universal standards are built on a non-universal sample, and why precision medicine is the correction — where the gaps are most urgent, and how to build a practice that doesn't replicate them.

A clinical masterclass in intravenous nutrient therapy for longevity — the evidence rationale for IV over oral, patient selection and safety screening, and protocol design for the core longevity infusions. Moves from didactic grounding to physician-led protocol design to hands-on line setup, access, and compounding.

An evidence review and hands-on workshop in regenerative therapies: PRP preparation, ultrasound-guided injection, and protein concentrates. Covers grading the evidence across joint, hair, and sexual-health applications, exosome sourcing and safety, and protocol design with consent frameworks and outcome tracking.

Peptide therapy is one of the most requested conversations in longevity medicine — and one of the most legally misunderstood, with a regulatory landscape that has shifted significantly in the past 18 months. This workshop puts legal counsel at the table alongside the clinical protocols.

Dr. Holden reframes aesthetic medicine as a clinical longevity discipline, not a cosmetic adjunct. A hands-on workshop covering a five-step framework for skin assessment and practical training in HiFem technology, collagen stimulators, and injectables with proper patient evaluation.

We still manage behavioral health and longevity in snapshots while the signals that predict trajectory — sleep, HRV, activity, recovery, mood — stream continuously and go unused. This session explores how wearable data feeding LLM-guided monitoring moves care from episodic to continuous, and names the hard parts honestly: alert fatigue, liability for autonomous management, and reimbursement.

The science of longevity medicine is advancing faster than the reimbursement system that supports it. Drawing on years building a concierge precision-medicine practice, Dr. Desai covers the architecture of a longevity practice that lasts: cash-pay versus hybrid models, membership design, concierge economics, and the patient experience that sustains trust.

Sarcopenia isn't a geriatric problem — it starts in the fourth decade and is measurable before it's visible. This session reframes it from decline prevention to performance preservation: assessing muscle mass and function, prescribing resistance and balance training with the specificity of a pharmacological protocol, and using force plates and body-composition data to set patient-specific targets.

Brain aging begins decades before any memory symptoms appear, which leaves a long window in which it can be measured and changed. This session covers what the research now shows about the biological age of the brain, how it is assessed through genomics, imaging, and cognitive testing, and which lifestyle and medical interventions have evidence supporting them. Attendees will leave with a framework for tracking their patients' rate of brain aging and lowering their dementia risk, along with a clear sense of where the evidence is solid and where it is still developing.

A diagnostics-forward workshop that treats performance as a vital sign: VO2 max benchmarks and mortality risk, force-plate analysis for fall and frailty risk, body-composition thresholds, and grip strength as a systemic longevity predictor. Small groups build a clinical movement-assessment battery, with hands-on device training.

An evidence review and hands-on workshop in regenerative therapies: PRP preparation, ultrasound-guided injection, and protein concentrates. Covers grading the evidence across joint, hair, and sexual-health applications, exosome sourcing and safety, and protocol design with consent frameworks and outcome tracking.

The downstream aesthetic consequences of GLP-1 therapy — facial volume loss, skin laxity, hair loss, muscle wasting — are creating a new patient category. This workshop establishes the framework for identifying, counseling, and treating these patients, with hands-on training in clinical evaluation and device-based therapies including PRF, Fotona laser, and topical exosomes.